Evidence map›Paper›PMID 38946721›Full record

ArticleJournal of cell communication and signaling2024

CircORC2 promoted proliferation and inhibited the sensitivity of osteosarcoma cell lines to cisplatin by regulating the miR-485-3p/TRIM2 axis.

Tianhua Chen, Zuyang Zhang, Chao Tian, Yuchao Feng, Xiaojie He, Liangdong Jiang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cell communication and signaling, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Tianhua ChenThe Affiliated Changsha Central Hospital Department of Orthopaedics Hengyang Medical School University of South China Changsha Hunan Province China.
Zuyang ZhangThe Affiliated Changsha Central Hospital Department of Orthopaedics Hengyang Medical School University of South China Changsha Hunan Province China.
Chao TianThe Affiliated Changsha Central Hospital Department of Orthopaedics Hengyang Medical School University of South China Changsha Hunan Province China.
Yuchao FengThe Affiliated Changsha Central Hospital Department of Orthopaedics Hengyang Medical School University of South China Changsha Hunan Province China.
Xiaojie HeLaboratory of Pediatric Nephrology Institute of Pediatrics Central South University Changsha Hunan Province China.
Liangdong JiangThe Affiliated Changsha Central Hospital Department of Orthopaedics Hengyang Medical School University of South China Changsha Hunan Province China.ORCID https://orcid.org/0000-0001-5876-9574

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Resistance to chemotherapy leads to poor prognosis for osteosarcoma (OS) patients. However, due to the high metastasis of tumor and the decrease in sensitivity of tumor cells to cisplatin (DDP), the 5-year survival rate of OS patients is still unsatisfactory. This study explored a mechanism for improving the sensitivity of OS cells to DDP. A DDP-resistant OS cell model was established, and we have found that circORC2 and TRIM2 were upregulated in DDP-resistant OS cells, but miR-485-3p was downregulated. The cell viability and proliferation of the OS cells decreased gradually with the increase of DDP dose, but a gradual increase in apoptosis was noted. CircORC2 promoted OS cell proliferation and DDP resistance and upregulated TRIM2 expression by targeting miR-485-3p. Functionally, circORC2 downregulated miR-485-3p to promote OS cell proliferation and inhibit DDP sensitivity. Additionally, it promoted cell proliferation and inhibited the sensitivity of DDP by regulating the miR-485-3p/TRIM2 axis. In conclusion, circORC2 promoted cell proliferation and inhibited the DDP sensitivity in OS cells via the miR-485-3p/TRIM2 axis. These findings indicated the role of circORC2 in regulating the sensitivity of OS cells to DDP.

Indexed as

circORC2cisplatin resistanceMiR‐485‐3posteosarcomaTRIM2

Identifiers

PMID38946721
PMCPMC11208123

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.